Search

Your search keyword '"Medford, Arielle"' showing total 121 results
Start Over Author "Medford, Arielle"
121 results on '"Medford, Arielle"'

3. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

Author

Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L., Shah, Ami N., Dai, Charles S., Reduzzi, Carolina, D’Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X., Bardia, Aditya, and Cristofanilli, Massimo

Published
2023
Full Text
View/download PDF

5. Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer.

Author

Podany, Emily L., primary, Foffano, Lorenzo, additional, Gerratana, Lorenzo, additional, Medford, Arielle J, additional, Clifton, Katherine, additional, Tapiavala, Shaili, additional, Velimirovic, Marko, additional, Lipsyc-Sharf, Marla, additional, Shah, Ami N., additional, Reduzzi, Carolina, additional, Munoz-Arcos, Laura Sofia, additional, Putur, Annika, additional, Ademuyiwa, Foluso Olabisi, additional, Puglisi, Fabio, additional, Ma, Cynthia X., additional, Bardia, Aditya, additional, Cristofanilli, Massimo, additional, and Davis, Andrew A., additional

Published
2024
Full Text
View/download PDF

7. Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study.

Author

Lipsyc-Sharf, Marla, primary, Fitzsimmons, Kasey, additional, Medford, Arielle J, additional, Podany, Emily L, additional, Sedrak, Mina S., additional, McAndrew, Nicholas Patrick, additional, Callahan, Rena Desai, additional, Kapoor, Nimmi S., additional, Master, Aashini K., additional, Rivero-Hinojosa, Samuel, additional, Fielder, Janie, additional, Rodriguez, Angel A, additional, Liu, Minetta C., additional, Knape, Justine, additional, Donahue, Jeannine, additional, Gianni, Caterina, additional, Davis, Andrew A., additional, Cristofanilli, Massimo, additional, and Bardia, Aditya, additional

Published
2024
Full Text
View/download PDF

8. CDK4/6 Inhibitor Efficacy in ESR1 -Mutant Metastatic Breast Cancer

Author

Lloyd, Maxwell R., primary, Brett, Jamie O., additional, Carmeli, Ariel, additional, Weipert, Caroline M., additional, Zhang, Nicole, additional, Yu, Junhua, additional, Bucheit, Leslie, additional, Medford, Arielle J., additional, Wagle, Nikhil, additional, Bardia, Aditya, additional, and Wander, Seth A., additional

Published
2024
Full Text
View/download PDF

10. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.

Author

Keenan, Jennifer C., Medford, Arielle J., Dai, Charles S., Wander, Seth A., Spring, Laura M., and Bardia, Aditya

Subjects
HORMONE receptor positive breast cancer, ESTROGEN receptors, METASTATIC breast cancer, CANCER patients, FULVESTRANT, CYCLIN-dependent kinase inhibitors
Abstract

Estrogen receptor positive (ER+) breast cancer is the most common breast cancer subtype, and therapeutic management relies primarily on inhibiting ER signaling. In the metastatic setting, ER signaling is typically targeted by selective estrogen receptor degraders (SERDs) or aromatase inhibitors (AIs), the latter of which prevent estrogen production. Activating ESR1 mutations are among the most common emergent breast cancer mutations and confer resistance to AIs. Until 2023, fulvestrant was the only approved SERD; fulvestrant is administered intramuscularly, and in some cases may also have limited efficacy in the setting of certain ESR1 mutations. In 2023, the first oral SERD, elacestrant, was approved for use in ESR1-mutated, ER+/HER2- advanced breast cancer and represents a new class of therapeutic options. While the initial approval was as monotherapy, ongoing studies are evaluating elacestrant (as well as other oral SERDs) in combination with other therapies including CDK4/6 inhibitors and PI3K inhibitors, which parallels the current combination uses of fulvestrant. Elacestrant's recent approval sheds light on the use of biomarkers such as ESR1 to gauge a tumor's endocrine sensitivity. Ongoing therapeutic and correlative biomarker studies will offer new insight and expanding treatment options for patients with advanced breast cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation

Author

Dalton, W. Brian, Helmenstine, Eric, Walsh, Noel, Gondek, Lukasz P., Kelkar, Dhanashree S., Read, Abigail, Natrajan, Rachael, Christenson, Eric S., Roman, Barbara, Das, Samarjit, Zhao, Liang, Leone, Robert D., Shinn, Daniel, Groginski, Taylor, Madugundu, Anil K., Patil, Arun, Zabransky, Daniel J., Medford, Arielle, Lee, Justin, Cole, Alex J., Rosen, Marc, Thakar, Maya, Ambinder, Alexander, Donaldson, Joshua, DeZern, Amy E., Cravero, Karen, Chu, David, Madero-Marroquin, Rafael, Pandey, Akhilesh, Hurley, Paula J., Lauring, Josh, and Park, Ben Ho

Subjects
Thermo Fisher Scientific Inc., Metabolites -- Health aspects -- Physiological aspects -- Genetic aspects, Genes -- Health aspects -- Physiological aspects -- Genetic aspects, Cells (Biology) -- Health aspects -- Physiological aspects -- Genetic aspects, Enzymes -- Health aspects -- Physiological aspects -- Genetic aspects, Serine -- Health aspects -- Physiological aspects -- Genetic aspects, Messenger RNA -- Health aspects -- Physiological aspects -- Genetic aspects, Glycine -- Health aspects -- Physiological aspects, Scientific equipment industry -- Health aspects -- Physiological aspects -- Genetic aspects, Amino acids, Cancer, RNA, Health care industry, Gene Ontology. Gene Ontology Consortium, Johns Hopkins University. School of Medicine
Abstract

Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of [SF3B1.sup.MUT] xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against [SF3B1.sup.MUT] cancers., Introduction Since their identification in 2011, mutations in spliceosome genes have been found in numerous human malignancies (1). Among the most broadly implicated genes is SF3B1, recurrently mutated in myelodysplastic [...]

Published
2019
Full Text
View/download PDF

13. Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.

Author

Spring, Laura M., Mortensen, Lindsey, Abraham, Elizabeth, Keenan, Jennifer, Medford, Arielle, Ma, Annie, Padden, Sarah, Denault, Elyssa, Ryan, Lianne, Iafrate, A. John, Lennerz, Jochen, Hochberg, Ephraim, Wander, Seth A., Moy, Beverly, Isakoff, Steven J., Juric, Dejan, Brennan, Kimberly A., Smith, Deborah E., Civiello, Barbara, and Mulvey, Therese

Subjects
BREAST tumor treatment, CLINICAL trials, HUMAN research subjects, METASTASIS, GENETIC testing, MEDICAL care, CANCER patients, SURVEYS, HUMAN services programs, CONCEPTUAL structures, QUALITY assurance, MEDICAL referrals, HEALTH care teams, GENOMICS, DATA analysis software, BREAST tumors, TELEMEDICINE
Abstract

PURPOSE There is a demand for improved care delivery surrounding genomic testing and clinical trial enrollment among patients with metastatic breast cancer (MBC). We sought to improve the current process via real-time informal consultation and prescreening assessment for patients with MBC treated by community and academic medical oncologists by implementing a virtual molecular and precision medicine (vMAP) clinic. METHODS The vMAP program used a virtual referral system directed to a multidisciplinary team with precision medicine expertise. Providers contacted vMAP regarding patients with MBC, and on receipt of referral, the vMAP team engaged in discussion to identify if further diagnostics were needed (including genomic testing) and to identify potential clinical trials or standard treatment options. Recommendations were then sent to the referring provider within 72 hours. Pre-/postsurveys were issued to network physicians to assess for barriers, clinical trial access, and vMAP referral experience. Program implementation was evaluated with the Squire 2.0 reporting guidelines for quality improvement in health care as a framework. RESULTS Eighty-one cases from 22 providers were referred to vMAP over a 26-month period. The average response time to the referring provider with a finalized recommendation was 1.90 ± 1.82 days. A total of 86.4% of cases had clinical trial options on vMAP prescreen, with 40.7% initiating formal screening assessments and 27 patients (33.3%) ultimately enrolling on trials. On resurvey, 92% of survey responses across community oncology referring providers said that they were very likely to use vMAP again. CONCLUSION In the initial 2-year period, vMAP demonstrated an efficient means to offer real-time interpretation of genomic testing and identification of clinical trials for patients with MBC, with effective clinical trial enrollment and high rates of referring provider satisfaction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Data from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

16. Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

17. Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

19. Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

21. Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, additional, Clifton, Katherine, additional, Medford, Arielle J., additional, Velimirovic, Marko, additional, Shah, Ami N., additional, D'Amico, Paolo, additional, Reduzzi, Carolina, additional, Zhang, Qiang, additional, Dai, Charles S., additional, Denault, Elyssa N., additional, Bagegni, Nusayba A., additional, Opyrchal, Mateusz, additional, Ademuyiwa, Foluso O., additional, Bose, Ron, additional, Behdad, Amir, additional, Ma, Cynthia X., additional, Bardia, Aditya, additional, Cristofanilli, Massimo, additional, and Davis, Andrew A., additional

Published
2023
Full Text
View/download PDF

22. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis

Author

Gerratana, Lorenzo, primary, Davis, Andrew A., additional, Velimirovic, Marko, additional, Reduzzi, Carolina, additional, Clifton, Katherine, additional, Bucheit, Leslie, additional, Hensing, Whitney L., additional, Shah, Ami N., additional, Pivetta, Tania, additional, Dai, Charles S., additional, D'Amico, Paolo, additional, Wehbe, Firas, additional, Medford, Arielle, additional, Wander, Seth A., additional, Gradishar, William J., additional, Behdad, Amir, additional, Ma, Cynthia X., additional, Puglisi, Fabio, additional, Bardia, Aditya, additional, and Cristofanilli, Massimo, additional

Published
2023
Full Text
View/download PDF

24. Abstract 6744: Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: A multi-institutional analysis of incidence and clinical outcomes

Author

Medford, Arielle J., primary, Niemierko, Andrzej, additional, Hensing, Whitney L., additional, Davis, Andrew A., additional, Clifton, Katherine, additional, Keenan, Jennifer C., additional, Kiedrowski, Lesli, additional, Shah, Ami N., additional, Gerratana, Lorenzo, additional, Cristofanilli, Massimo, additional, and Bardia, Aditya, additional

Published
2023
Full Text
View/download PDF

25. SUPPLEMENTARY DATA from ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Author

Chu, David, primary, Paoletti, Costanza, primary, Gersch, Christina, primary, VanDenBerg, Dustin A., primary, Zabransky, Daniel J., primary, Cochran, Rory L., primary, Wong, Hong Yuen, primary, Toro, Patricia Valda, primary, Cidado, Justin, primary, Croessmann, Sarah, primary, Erlanger, Bracha, primary, Cravero, Karen, primary, Kyker-Snowman, Kelly, primary, Button, Berry, primary, Parsons, Heather A., primary, Dalton, W. Brian, primary, Gillani, Riaz, primary, Medford, Arielle, primary, Aung, Kimberly, primary, Tokudome, Nahomi, primary, Chinnaiyan, Arul M., primary, Schott, Anne, primary, Robinson, Dan, primary, Jacks, Karen S., primary, Lauring, Josh, primary, Hurley, Paula J., primary, Hayes, Daniel F., primary, Rae, James M., primary, and Park, Ben Ho, primary

Published
2023
Full Text
View/download PDF

26. Data from ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Author

Chu, David, primary, Paoletti, Costanza, primary, Gersch, Christina, primary, VanDenBerg, Dustin A., primary, Zabransky, Daniel J., primary, Cochran, Rory L., primary, Wong, Hong Yuen, primary, Toro, Patricia Valda, primary, Cidado, Justin, primary, Croessmann, Sarah, primary, Erlanger, Bracha, primary, Cravero, Karen, primary, Kyker-Snowman, Kelly, primary, Button, Berry, primary, Parsons, Heather A., primary, Dalton, W. Brian, primary, Gillani, Riaz, primary, Medford, Arielle, primary, Aung, Kimberly, primary, Tokudome, Nahomi, primary, Chinnaiyan, Arul M., primary, Schott, Anne, primary, Robinson, Dan, primary, Jacks, Karen S., primary, Lauring, Josh, primary, Hurley, Paula J., primary, Hayes, Daniel F., primary, Rae, James M., primary, and Park, Ben Ho, primary

Published
2023
Full Text
View/download PDF

27. Abstract PD10-01: PD10-01 Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach

Author

Gerratana, Lorenzo, primary, Roncato, Rossana, additional, Sturlese, Mattia, additional, Davis, Andrew A., additional, Velimirovic, Marko, additional, REDUZZI, Carolina, additional, Clifton, Katherine K., additional, Hensing, Whitney L., additional, Shah, Ami N., additional, Dai, Charles S., additional, D’Amico, Paolo, additional, Medford, Arielle J., additional, Franzoni, Alessandra, additional, Cucciniello, Linda, additional, Wehbe, Firas, additional, Wander, Seth A., additional, Belletti, Barbara, additional, Gradishar, William, additional, Behdad, Amir, additional, Damante, Giuseppe, additional, Ma, Cynthia, additional, Puglisi, Fabio, additional, Bardia, Aditya, additional, and Cristofanilli, Massimo, additional

Published
2023
Full Text
View/download PDF

28. Abstract PD17-03: Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized HR+/HER2- breast cancer (LEADER)

Author

Medford, Arielle J., primary, Scarpetti, Lauren, additional, Niemierko, Andrzej, additional, Isakoff, Steven J., additional, Moy, Beverly, additional, Wander, Seth A., additional, Deluca, Elizabeth, additional, Abraham, Elizabeth, additional, Shin, Jennifer, additional, Schnipper, Lowell, additional, Comander, Amy E., additional, Mulvey, Therese, additional, Spickard, Erik, additional, Kalashnikova, Ekaterina, additional, Rodriguez, Angel, additional, Ellisen, Leif, additional, Bardia, Aditya, additional, and Spring, Laura M., additional

Published
2023
Full Text
View/download PDF

29. Abstract P1-08-01: Virtual molecular and precision medicine (vMAP) clinic to improve access to clinical trials for patients with metastatic breast cancer: an academic-community collaboration

Author

Mortensen, Lindsey, primary, Keenan, Jennifer C., additional, Abraham, Elizabeth, additional, Padden, Sarah, additional, Ma, Annie, additional, Denault, Elyssa, additional, Ryan, Lianne, additional, Medford, Arielle J., additional, Ellisen, Leif, additional, Schwartz, Joel H., additional, Bardia, Aditya, additional, and Spring, Laura M., additional

Published
2023
Full Text
View/download PDF

30. Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis

Author

Medford, Arielle J., primary, Velimirovic, Marko, additional, Niemierko, Andrzej, additional, Hensing, Whitney L., additional, Davis, Andrew A., additional, Clifton, Katherine K., additional, Keenan, Jennifer C., additional, Dai, Charles S., additional, Kiedrowski, Lesli A., additional, Shah, Ami N., additional, Gerratana, Lorenzo, additional, Spring, Laura M., additional, Ellisen, Leif, additional, Doebele, Robert C., additional, Cristofanilli, Massimo, additional, and Bardia, Aditya, additional

Published
2023
Full Text
View/download PDF

31. Abstract P5-02-13: TRK inhibitor in a patient with metastatic triple negative breast cancer and NTRK fusions identified via cell-free DNA analysis

Author

Keenan, Jennifer C., primary, Medford, Arielle J., additional, Oshry, Lauren J., additional, Boyraz, Baris, additional, Dai, Charles S., additional, Kiedrowski, Lesli A., additional, Menshikova, Sofia, additional, Butusova, Anna, additional, Gogakos, Tasos, additional, Occhiogrosso, Rachel, additional, Ryan, Phoebe, additional, Lennerz, Jochen, additional, Spring, Laura M., additional, Moy, Beverly, additional, Ellisen, Leif, additional, and Bardia, Aditya, additional

Published
2023
Full Text
View/download PDF

32. Abstract P1-13-07: Investigating NF1 Mutations in Circulating Tumor DNA of Patients with Hormone-receptor Positive (HR+) Breast Tumors Resistant to CDK4/6 Inhibition (CDK4/6i): A Retrospective Clinical Analysis

Author

Lloyd, Maxwell R., primary, Ryan, Lianne, additional, Medford, Arielle J., additional, Keenan, Jennifer C., additional, Spring, Laura M., additional, Vidula, Neelima, additional, Moy, Beverly, additional, Juric, Dejan, additional, Ellisen, Leif, additional, Bardia, Aditya, additional, and Wander, Seth A., additional

Published
2023
Full Text
View/download PDF

34. TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis

Author

Medford, Arielle J., primary, Oshry, Lauren, additional, Boyraz, Baris, additional, Kiedrowski, Lesli, additional, Menshikova, Sofia, additional, Butusova, Anna, additional, Dai, Charles S., additional, Gogakos, Tasos, additional, Keenan, Jennifer C., additional, Occhiogrosso, Rachel H., additional, Ryan, Phoebe, additional, Lennerz, Jochen K., additional, Spring, Laura M., additional, Moy, Beverly, additional, Ellisen, Leif W., additional, and Bardia, Aditya, additional

Published
2023
Full Text
View/download PDF

37. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

Author

Medford, Arielle J., Dubash, Taronish D., Juric, Dejan, Spring, Laura, Niemierko, Andrzej, Vidula, Neelima, Peppercorn, Jeffrey, Isakoff, Steven, Reeves, Brittany A., LiCausi, Joseph A., Wesley, Benjamin, Malvarosa, Giuliana, Yuen, Megan, Wittner, Ben S., Lawrence, Michael S., Iafrate, A. John, Ellisen, Leif, Moy, Beverly, Toner, Mehmet, Maheswaran, Shyamala, Haber, Daniel A., and Bardia, Aditya

Published
2019
Full Text
View/download PDF

38. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

Author

Davis, Andrew A., primary, Gerratana, Lorenzo, additional, Clifton, Katherine, additional, Medford, Arielle J., additional, Velimirovic, Marko, additional, Hensing, Whitney L., additional, Bucheit, Leslie, additional, Shah, Ami N., additional, D'Amico, Paolo, additional, Reduzzi, Carolina, additional, Zhang, Qiang, additional, Dai, Charles S., additional, Denault, Elyssa N., additional, Bagegni, Nusayba A., additional, Opyrchal, Mateusz, additional, Ademuyiwa, Foluso O., additional, Bose, Ron, additional, Gradishar, William J., additional, Behdad, Amir, additional, Ma, Cynthia X., additional, Bardia, Aditya, additional, and Cristofanilli, Massimo, additional

Published
2022
Full Text
View/download PDF

39. Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).

Author

Gerratana, Lorenzo, primary, Reduzzi, Carolina, additional, Davis, Andrew A., additional, Velimirovic, Marko, additional, Clifton, Katherine, additional, Hensing, Whitney L, additional, Shah, Ami N., additional, Dai, Charles Sichao, additional, D’Amico, Paolo, additional, Donahue, Jeannine, additional, Zhang, Qiang, additional, Membrino, Alexandro, additional, Wehbe, Firas Hazem, additional, Medford, Arielle Janine, additional, Gradishar, William John, additional, Behdad, Amir, additional, Ma, Cynthia X., additional, Wander, Seth Andrew, additional, Puglisi, Fabio, additional, and Cristofanilli, Massimo, additional

Published
2022
Full Text
View/download PDF

41. Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies.

Author

Keenan, Jennifer C., Ryan, Phoebe K., Medford, Arielle J., Spring, Laura M., and Bardia, Aditya

Subjects
BREAST cancer, TRIPLE-negative breast cancer, CANCER treatment, THERAPEUTICS, IMMUNOTHERAPY
Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease that is historically difficult to treat, but advances in molecular targeted therapies, including the use of antibodies, are changing the standard of care. Translational research over the years has revealed various actionable targets allowing TNBC to be subtyped in novel ways. In this article, we review the molecular targets that guide current management of patients with metastatic TNBC (mTNBC), including programmed death-ligand 1, germline BRCA1 and BRCA2 mutations, and the transmembrane glycoprotein Trop-2. These targets allow for the treatment of mTNBC with immunotherapy, poly(ADP-ribose)polymerase inhibitors, and antibody-drug conjugates (ADC), such as sacituzumab govitecan, the first ADC approved for the treatment of breast cancer. We also review upcoming therapies, such as datopotamab deruxtecan and trastuzumab deruxtecan. Although mTNBC is complex in nature, molecular studies are making treatments more personalized by identifying actionable targets in what was once thought to be a nontargetable disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice

Author

Patel, Seema R., Cadwell, Chantel M., Medford, Arielle, and Zimring, James C.

Subjects
Bone marrow -- Transplantation, Histocompatibility antigens, HLA histocompatibility antigens, Antibodies, Viral antibodies
Abstract

Bone marrow transplantation (BMT) represents a cure for nonmalignant hematological disorders. However, compared with the stringent conditioning regimens used when performing BMT to treat hematological malignancies, the reduced intensity conditioning regimen used in the context of nonmalignant hematological disorders leads to substantially higher rates of BMT rejection, presumably due to an intact immune system. The relevant patient population typically receives transfusion support, often including platelets, and the frequency of BMT rejection correlates with the frequency of transfusion. Here, we demonstrate that immunity to transfused platelets contributes to subsequent BMT rejection in mice, even when the BMT donor and recipient are MHC matched. We used MHC-matched bone marrow because, although immunity to transfused platelets is best characterized in relation to HLA-specific antibodies, such antibodies are unlikely to play a role in clinical BMT rejection that is HLA matched. However, bone marrow is not matched in the clinic for minor histocompatibility antigens, such as those carried by platelets, and we report that transfusion of minor histocompatibility antigen-mismatched platelets induced subsequent BMT rejection. These findings indicate previously unappreciated sequelae of immunity to platelets in the context of transplantation and suggest that strategies to account for minor histocompatibility mismatching may help to reduce the chance of BMT rejection in human patients., Introduction Patients who have bone marrow failure syndromes are typically given supportive care, including transfusions of rbc and platelets (PLTs). Some marrow failure patients subsequently undergo bone marrow transplantation (BMT) [...]

Published
2009
Full Text
View/download PDF

44. Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer

Author

Dai, Charles, primary, Niemierko, Andrzej, additional, Vidula, Neelima, additional, Spring, Laura M, additional, Wander, Seth A, additional, Medford, Arielle J, additional, Hesler, Katherine A, additional, Malvarosa, Giuliana, additional, Peppercorn, Jeffrey, additional, Juric, Dejan, additional, Isakoff, Steven J, additional, Moy, Beverly, additional, Ellisen, Leif W, additional, and Bardia, Aditya, additional

Published
2021
Full Text
View/download PDF

45. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer

Author

Velimirovic, Marko, primary, Juric, Dejan, additional, Niemierko, Andrzej, additional, Spring, Laura, additional, Vidula, Neelima, additional, Wander, Seth A., additional, Medford, Arielle, additional, Parikh, Aparna, additional, Malvarosa, Giuliana, additional, Yuen, Megan, additional, Corcoran, Ryan, additional, Moy, Beverly, additional, Isakoff, Steven J., additional, Ellisen, Leif W., additional, Iafrate, Anthony, additional, Chabner, Bruce, additional, and Bardia, Aditya, additional

Published
2020
Full Text
View/download PDF

47. Abstract 1408: SF3B1 mutations induce proteome remodeling, metabolic reprogramming, and a novel kind of tumor surface antigen in human cells

Author

Dalton, William B., primary, Shinn, Daniel, additional, Walsh, Noel, additional, Christenson, Eric, additional, Groginski, Taylor, additional, Kelkar, Dhanashree, additional, Magugundu, Anil, additional, Patil, Arun, additional, Zabransky, Daniel, additional, Medford, Arielle, additional, Lee, Justin, additional, Cole, Alex, additional, Donaldson, Josh, additional, DeZern, Amy, additional, Cravero, Karen, additional, Chu, David, additional, Hunter, Natasha, additional, Pandey, Akhilesh, additional, Lauring, Josh, additional, and Park, Ben, additional

Published
2018
Full Text
View/download PDF

48. Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.

Author

Medford, Arielle, primary, Niemierko, Andrzej, additional, Moy, Beverly, additional, Spring, Laura, additional, Malvarosa, Giuliana, additional, Younger, Jerry, additional, Lanman, Richard B., additional, Nagy, Rebecca J, additional, Corcoran, Ryan Bruce, additional, Isakoff, Steven J., additional, Ellisen, Leif W., additional, Juric, Dejan, additional, and Bardia, Aditya, additional

Published
2018
Full Text
View/download PDF

49. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Author

Chu, David, primary, Paoletti, Costanza, additional, Gersch, Christina, additional, VanDenBerg, Dustin A., additional, Zabransky, Daniel J., additional, Cochran, Rory L., additional, Wong, Hong Yuen, additional, Toro, Patricia Valda, additional, Cidado, Justin, additional, Croessmann, Sarah, additional, Erlanger, Bracha, additional, Cravero, Karen, additional, Kyker-Snowman, Kelly, additional, Button, Berry, additional, Parsons, Heather A., additional, Dalton, W. Brian, additional, Gillani, Riaz, additional, Medford, Arielle, additional, Aung, Kimberly, additional, Tokudome, Nahomi, additional, Chinnaiyan, Arul M., additional, Schott, Anne, additional, Robinson, Dan, additional, Jacks, Karen S., additional, Lauring, Josh, additional, Hurley, Paula J., additional, Hayes, Daniel F., additional, Rae, James M., additional, and Park, Ben Ho, additional

Published
2016
Full Text
View/download PDF

50. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

Author

Cidado, Justin, primary, Wong, Hong Yuen, additional, Rosen, D. Marc, additional, Cimino-Mathews, Ashley, additional, Garay, Joseph P., additional, Fessler, Abigail G., additional, Rasheed, Zeshaan A., additional, Hicks, Jessica, additional, Cochran, Rory L., additional, Croessmann, Sarah, additional, Zabransky, Daniel J., additional, Mohseni, Morassa, additional, Beaver, Julia A., additional, Chu, David, additional, Cravero, Karen, additional, Christenson, Eric S., additional, Medford, Arielle, additional, Mattox, Austin, additional, De Marzo, Angelo M., additional, Argani, Pedram, additional, Chawla, Ajay, additional, Hurley, Paula J., additional, Lauring, Josh, additional, and Park, Ben Ho, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results